155 related articles for article (PubMed ID: 25202052)
21. Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinoma.
Yu J; Ploner A; Kordes M; Löhr M; Nilsson M; de Maturana MEL; Estudillo L; Renz H; Carrato A; Molero X; Real FX; Malats N; Ye W
Int J Cancer; 2021 Apr; 148(8):2048-2058. PubMed ID: 33411965
[TBL] [Abstract][Full Text] [Related]
22. The diagnostic, predictive, and prognostic role of serum epithelial cell adhesion molecule (EpCAM) and vascular cell adhesion molecule-1 (VCAM-1) levels in breast cancer.
Karabulut S; Tas F; Tastekin D; Karabulut M; Yasasever CT; Ciftci R; Güveli M; Fayda M; Vatansever S; Serilmez M; Disci R; Aydıner A
Tumour Biol; 2014 Sep; 35(9):8849-60. PubMed ID: 24891186
[TBL] [Abstract][Full Text] [Related]
23. Clinical significance of serum Wisteria floribunda agglutinin-positive Mac-2 binding protein in pancreatic ductal adenocarcinoma.
Waragai Y; Suzuki R; Takagi T; Sugimoto M; Asama H; Watanabe K; Kikuchi H; Hikichi T; Masamune A; Kang Y; Fleming JB; Ohira H
Pancreatology; 2016; 16(6):1044-1050. PubMed ID: 27665173
[TBL] [Abstract][Full Text] [Related]
24. Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma.
Schulze K; Gasch C; Staufer K; Nashan B; Lohse AW; Pantel K; Riethdorf S; Wege H
Int J Cancer; 2013 Nov; 133(9):2165-71. PubMed ID: 23616258
[TBL] [Abstract][Full Text] [Related]
25. Accurate discrimination of pancreatic ductal adenocarcinoma and chronic pancreatitis using multimarker expression data and samples obtained by minimally invasive fine needle aspiration.
Chen Y; Zheng B; Robbins DH; Lewin DN; Mikhitarian K; Graham A; Rumpp L; Glenn T; Gillanders WE; Cole DJ; Lu X; Hoffman BJ; Mitas M
Int J Cancer; 2007 Apr; 120(7):1511-7. PubMed ID: 17192896
[TBL] [Abstract][Full Text] [Related]
26. Serum Mac-2 binding protein is a novel biomarker for chronic pancreatitis.
Maekawa T; Kamada Y; Ebisutani Y; Ueda M; Hata T; Kawamoto K; Takamatsu S; Mizutani K; Shimomura M; Sobajima T; Fujii H; Nakayama K; Nishino K; Yamada M; Kumada T; Ito T; Eguchi H; Nagano H; Miyoshi E
World J Gastroenterol; 2016 May; 22(17):4403-10. PubMed ID: 27158210
[TBL] [Abstract][Full Text] [Related]
27. A novel serum metabolomics-based diagnostic approach to pancreatic cancer.
Kobayashi T; Nishiumi S; Ikeda A; Yoshie T; Sakai A; Matsubara A; Izumi Y; Tsumura H; Tsuda M; Nishisaki H; Hayashi N; Kawano S; Fujiwara Y; Minami H; Takenawa T; Azuma T; Yoshida M
Cancer Epidemiol Biomarkers Prev; 2013 Apr; 22(4):571-9. PubMed ID: 23542803
[TBL] [Abstract][Full Text] [Related]
28. Identification of a novel serum biomarker for pancreatic cancer, C4b-binding protein α-chain (C4BPA) by quantitative proteomic analysis using tandem mass tags.
Sogawa K; Takano S; Iida F; Satoh M; Tsuchida S; Kawashima Y; Yoshitomi H; Sanda A; Kodera Y; Takizawa H; Mikata R; Ohtsuka M; Shimizu H; Miyazaki M; Yokosuka O; Nomura F
Br J Cancer; 2016 Oct; 115(8):949-956. PubMed ID: 27657339
[TBL] [Abstract][Full Text] [Related]
29. Predicting factors for unresectability in patients with pancreatic ductal adenocarcinoma.
Okada K; Kawai M; Tani M; Hirono S; Miyazawa M; Shimizu A; Kitahata Y; Yamaue H
J Hepatobiliary Pancreat Sci; 2014 Sep; 21(9):648-53. PubMed ID: 24764208
[TBL] [Abstract][Full Text] [Related]
30. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis.
Mayerle J; Kalthoff H; Reszka R; Kamlage B; Peter E; Schniewind B; González Maldonado S; Pilarsky C; Heidecke CD; Schatz P; Distler M; Scheiber JA; Mahajan UM; Weiss FU; Grützmann R; Lerch MM
Gut; 2018 Jan; 67(1):128-137. PubMed ID: 28108468
[TBL] [Abstract][Full Text] [Related]
31. Clinical and prognostic significance of serum transforming growth factor-beta1 levels in patients with pancreatic ductal adenocarcinoma.
Zhao J; Liang Y; Yin Q; Liu S; Wang Q; Tang Y; Cao C
Braz J Med Biol Res; 2016 Jul; 49(8):. PubMed ID: 27464025
[TBL] [Abstract][Full Text] [Related]
32. Circulating Protein Biomarkers for Use in Pancreatic Ductal Adenocarcinoma Identification.
Lindgaard SC; Sztupinszki Z; Maag E; Chen IM; Johansen AZ; Jensen BV; Bojesen SE; Nielsen DL; Hansen CP; Hasselby JP; Nielsen KR; Szallasi Z; Johansen JS
Clin Cancer Res; 2021 May; 27(9):2592-2603. PubMed ID: 33737308
[TBL] [Abstract][Full Text] [Related]
33. Clinical significance of serum epithelial cell adhesion molecule (EPCAM) and vascular cell adhesion molecule-1 (VCAM-1) levels in patients with epithelial ovarian cancer.
Tas F; Karabulut S; Serilmez M; Ciftci R; Duranyildiz D
Tumour Biol; 2014 Apr; 35(4):3095-102. PubMed ID: 24307621
[TBL] [Abstract][Full Text] [Related]
34. Clinical significance of serum levels of immune-associated molecules, uric acid and soluble MHC class I chain-related molecules A and B, as diagnostic tumor markers for pancreatic ductal adenocarcinoma.
Chung HW; Lim JB
Cancer Sci; 2011 Sep; 102(9):1673-9. PubMed ID: 21615621
[TBL] [Abstract][Full Text] [Related]
35. Dysbindin as a novel biomarker for pancreatic ductal adenocarcinoma identified by proteomic profiling.
Guo X; Lv X; Fang C; Lv X; Wang F; Wang D; Zhao J; Ma Y; Xue Y; Bai Q; Yao X; Chen Y
Int J Cancer; 2016 Oct; 139(8):1821-9. PubMed ID: 27281120
[TBL] [Abstract][Full Text] [Related]
36. Comparison of the tumor cell secretome and patient sera for an accurate serum-based diagnosis of pancreatic ductal adenocarcinoma.
Mustafa S; Pan L; Marzoq A; Fawaz M; Sander L; Rückert F; Schrenk A; Hartl C; Uhler R; Yildirim A; Strobel O; Hackert T; Giese N; Büchler MW; Hoheisel JD; Alhamdani MS
Oncotarget; 2017 Feb; 8(7):11963-11976. PubMed ID: 28060763
[TBL] [Abstract][Full Text] [Related]
37. Serum fibrinogen as a diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma.
Chung KH; Lee JC; Lee J; Cho IK; Kim J; Jang W; Yoo BC; Hwang JH
Pancreatology; 2020 Oct; 20(7):1465-1471. PubMed ID: 32873483
[TBL] [Abstract][Full Text] [Related]
38. Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma.
Poruk KE; Firpo MA; Scaife CL; Adler DG; Emerson LL; Boucher KM; Mulvihill SJ
Pancreas; 2013 Mar; 42(2):193-7. PubMed ID: 23407481
[TBL] [Abstract][Full Text] [Related]
39. Tumour budding is a strong and independent prognostic factor in pancreatic cancer.
Karamitopoulou E; Zlobec I; Born D; Kondi-Pafiti A; Lykoudis P; Mellou A; Gennatas K; Gloor B; Lugli A
Eur J Cancer; 2013 Mar; 49(5):1032-9. PubMed ID: 23177090
[TBL] [Abstract][Full Text] [Related]
40. Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma.
Jin A; Xu Y; Liu S; Jin T; Li Z; Jin H; Lin L; Lin Z
Exp Mol Pathol; 2014 Feb; 96(1):54-60. PubMed ID: 24263054
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]